1. Tobiásová Z, Pospísilová D, Miller AM, Minárik I, Sochorová K, Spísek R, Rob L, Bartůnková J: In vitro as- sessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. Clin Immunol 122;18-27, 2007
2. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR: Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186;65-70, 1997
3. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9;271-296, 1991
4. Morisaki T, Matsumoto K, Onishi H, Kuroki H, Baba E, Tasaki A, Kubo M, Nakamura M, Inaba S, Yamaguchi K, Tanaka M, Katano M: Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 16;175-182, 2003
5. Rock KL, Clark K. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 156;3721-3726, 1996
6. Salio M, Cerundolo V, Lanzavecchia A: Dendritic cell maturation is induced by mycoplasma infection but not by ne- crotic cells. Eur J Immunol 30;705-708, 2000
7. Shimizu K, Thomas EK, Giedlin M, Mulé JJ: Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 61;2618-2624, 2001
8. Jeannin P, Renno T, Goetsch L, Miconnet I, Aubry JP, Delneste Y, Herbault N, Baussant T, Magistrelli G, Soulas C, Romero P, Cerottini JC, Bonnefoy JY: OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol 1;502-509, 2000
9. Sloan JM, Kershaw MH, Touloukian CE, Lapointe R, Robbins PF, Restifo NP, Hwu P: MHC class I and class II presentation of tumor antigen in retrovirally and adenovir- ally transduced dendritic cells. Cancer Gene Ther 9;946- 950, 2002
10. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392;86-89, 1998
11. You Z, Hester J, Rollins L, Spagnoli GC, van der Bruggen P, Chen SY: A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res 61;197-205, 2001
12. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific 
13. Huang J, Tatsumi T, Pizzoferrato E, Vujanovic N, Storkus WJ: Nitric oxide sensitizes tumor cells to dendritic cell- mediated apoptosis, uptake, and cross-presentation. Cancer Res 65;8461-8470, 2005
14. Liu Y, Bi X, Xu S, Xiang J: Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses. Cancer Res 65; 4955-4962, 2005
15. Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey D, Walsh K, Sweeney C, Leavy O, Fletcher J, Lavelle EC, Dunne P, Mills KH: Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 180; 3797-3806, 2008
16. Zanoni I, Foti M, Ricciardi-Castagnoli P, Granucci F: TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells. J Immunol 175;286-292, 2005
17. Kane CM, Cervi L, Sun J, McKee AS, Masek KS, Shapira S, Hunter CA, Pearce EJ: Helminth antigens modulate TLR-initiated dendritic cell activation. J Immunol 173;7454- 7461, 2004
18. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5;471-484, 2006